Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401183 | 1.00 | SIRT2 (0.53) | SIRT2ACENMBRPPARAPPARG | |
| SCHEMBL5349888 | 1.00 | SIRT2 (0.53) | SIRT2ACENMBRPPARAPPARG | |
| SCHEMBL29606071 | 0.94 | SIRT2 (0.50) | SIRT2ACENMBRPPARAPPARG | |
| SCHEMBL13810396 | 0.92 | SIRT2 (0.61) | SIRT2NMBR | |
| SCHEMBL11913040 | 0.92 | SIRT2 (0.61) | SIRT2NMBR | |
| SCHEMBL30053690 | 0.90 | NMBR (0.49) | SIRT2NMBR | |
| SCHEMBL28994991 | 0.90 | SIRT2 (0.58) | SIRT2NMBR | |
| SCHEMBL28994992 | 0.90 | SIRT2 (0.58) | SIRT2NMBR | |
| SCHEMBL18367552 | 0.89 | SIRT2 (0.49) | SIRT2NMBR | |
| SCHEMBL29040245 | 0.89 | SIRT2 (0.49) | SIRT2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| US-12577274-B2 | Manufacture of glucagon peptides | BACHEM HOLDING AG (CH) | 2026-03-17 | — | — | US | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| WO-2025098464-A1 | INTERMEDIATE FOR PREPARING GLUCAGON AND GLP-1 DUAL AGONIST AND PREPARATION METHOD THEREFOR | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | claimed |
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | claimed |
| CN-119798083-A | Iron-catalyzed aromatic compound carbon-hydrogen bond hydroxylation nitration method | 南京师范大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119798407-A | Incretin analogue with multiple biological activities, synthesis method, pharmaceutical composition and application | 江苏食品药品职业技术学院 | 2025-04-11 | — | — | CN | claimed |
| CN-119798062-A | Method for catalyzing quinone hydroxylation reaction of alkene by iron | 南京师范大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119798139-A | Method for synthesizing phenolic compound by iron-catalyzed hydroxylation reaction of aromatic compound | 南京师范大学 | 2025-04-11 | — | — | CN | claimed |
| CN-114685645-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-3433267-B1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2022-08-24 | — | — | EP | claimed |
| CN-114685645-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-112961054-B | Method for iron-catalyzed ethoxycarbonyl difluoromethylation of aromatic compound | 南京师范大学 | 2022-06-03 | — | — | CN | claimed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | claimed |
| US-20220143150-A1 | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST ANALOG, PROCESS OF PREPARATION AND USES THEREOF | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-12 | — | — | US | claimed |
| CN-114426441-A | Method for catalyzing chlorination of quinone compounds by iron | 南京师范大学 | 2022-05-03 | — | — | CN | claimed |
| CN-114315957-A | Preparation method of polypeptide | 深圳瑞德林生物技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-112961054-A | Method for iron-catalyzed ethoxycarbonyl difluoromethylation of aromatic compound | 南京师范大学 | 2021-06-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | SIRT2 1051/4885ACE 1683/4885NMBR 432/4885 |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | SIRT2 1962/4885ACE 2676/4885NMBR 322/4885 |
| US-12577274-B2 | Manufacture of glucagon peptides | IAPP, GLP1R, GCG | SIRT2 3554/4885ACE 1821/4885NMBR 2223/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | SIRT2 2276/4885ACE 2876/4885NMBR 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.